Catalysts for Libtayo
17 tracked
Apr 30, 2026
phase 2 completion
Regeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)
cemiplimab
→
Apr 30, 2026
phase 1 completion
OncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)
cemiplimab
→
Oct 29, 2025
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Oct 8, 2025
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 5, 2024
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Mar 6, 2024
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 28, 2023
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Apr 28, 2023
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Nov 8, 2022
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 22, 2021
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 9, 2021
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Feb 9, 2021
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Nov 10, 2020
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Jun 25, 2020
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Mar 20, 2019
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Jan 18, 2019
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→
Sep 28, 2018
approval
LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval
cemiplimab
→